Management Approach for Residual and Recurrent Mitral Regurgitation After Transcatheter Edge-to-Edge Repair
Recommended Citation
Fang JX, Giustino G, So KC, Stolz L, Marin-Cuartas M, Maznyczka A, Baron SJ, Khan JM, Chen M, Taramasso M, Seshiah P, Denti P, Lee APW, Calvert PA, Swanns MJ, Rogers T, Singh GD, Ailawadi G, Hausleiter J, George I, Borger MA, Sievert H, Maisano F, Alfieri O, de Backer O, Wang DD, McCabe JM, Hahn RT, Tang GHL, Villablanca PA. Management Approach for Residual and Recurrent Mitral Regurgitation After Transcatheter Edge-to-Edge Repair. JACC Cardiovasc Interv. 2026;19(9):1071-1086.
Document Type
Article
Publication Date
5-11-2026
Publication Title
JACC Cardiovasc Interv
Keywords
Humans, Mitral Valve Insufficiency, Recurrence, Mitral Valve, Cardiac Catheterization, Treatment Outcome, Heart Valve Prosthesis Implantation, Risk Factors, Recovery of Function, Severity of Illness Index, Hemodynamics
Abstract
Mitral valve transcatheter edge-to-edge repair (M-TEER) is an established treatment option for patients with severe mitral regurgitation (MR) at high risk for surgery. However, the rate of recurrent MR ≥ 3+ after M-TEER may be up to 10% at 1 year. As the volume of M-TEER procedures increases, the number of patients experiencing recurrent MR post-TEER is also rising. M-TEER reshapes valve anatomy and complicates further treatment strategies for MR. In this review, the authors provide practical management considerations for patients with residual or recurrent MR after M-TEER.
Medical Subject Headings
Humans; Mitral Valve Insufficiency; Recurrence; Mitral Valve; Cardiac Catheterization; Treatment Outcome; Heart Valve Prosthesis Implantation; Risk Factors; Recovery of Function; Severity of Illness Index; Hemodynamics
PubMed ID
42120115
Volume
19
Issue
9
First Page
1071
Last Page
1086
